Rash News and Research

RSS

Study examines relationship between parental vaccine refusal and risk of varicella infection in children

Children of parents who refuse vaccines are nine times more likely to get chickenpox compared to fully immunized children, according to a new study led by a vaccine research team at Kaiser Permanente Colorado's Institute for Health Research.

5 Jan 2010

NMA urges parents to protect their children from meningococcal disease

This winter, while many parents are focused on influenza prevention, the National Meningitis Association (NMA) is urging parents to also protect their families from meningococcal disease, a deadly but potentially vaccine preventable bacterial infection.

22 Dec 2009

FDA Advisory Committee votes against the approval of Tarceva

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.

17 Dec 2009

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.

14 Dec 2009

Positive interim results of ARRY-380 in Phase 1 trial announced

Array BioPharma Inc. today announced positive interim results of its novel, small molecule HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in advanced cancer patients.

13 Dec 2009

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

A modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine.

13 Dec 2009

Health IT investments continue as security experts express concern

As the federal government prepares to invest up to $34 billion in health information technology and develop a plan to oversee it that includes special measures to protect privacy, a rash of news stories about e-health security breaches has raised questions, Modern Healthcare reports.

10 Dec 2009

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

9 Dec 2009

Native Remedies selects TransMedia Group as its PR firm

With more than 500,000 customers worldwide, the market leader in all-natural herbal and homeopathic remedies for people and their pets, Native Remedies, has engaged TransMedia Group as their PR firm of record. The company's two brands, Native Remedies (www.nativeremedies.com) and PetAlive (www.PetAlive.com), provide complete lines of safe, scientifically-tested, guaranteed products that promote health and wellness - naturally.

7 Dec 2009

Amgen announces results from three studies on the safety and efficacy of Nplate

Amgen Inc. today announced results from three studies on the safety and efficacy of Nplate® (romiplostim) in adult patients with myelodysplastic syndromes (MDS).

7 Dec 2009

Measles deaths decline worldwide by 78%, experts warn against complacency

Measles deaths fell from 733,000 in 2000 to 164,000 in 2008 - 78 percent - thanks, in part, to increased vaccination efforts that reached an estimated 700 million children, according to a report released Thursday by the U.S.-based Measles Initiative, Reuters reports.

4 Dec 2009

Study shows herbal medicine is effective for treating acute rhinosinusitis

Rhinosinusitis is an inflammatory process involving one or more of the paranasal sinuses that typically follows a viral upper respiratory tract infection (RTI). The term ‘acute rhinosinusitis’ is used instead of ‘acute sinusitis’ because it is the currently internationally accepted terminology.

4 Dec 2009

New Jersey hospitals fight to recover from economic downturn

The recession has dealt a significant blow to New Jersey hospitals, with a new report showing that the statewide 2008 hospital operating margin reached just 0.2 percent, the lowest point since 1999.

4 Dec 2009

Children vaccinated against chickenpox at much lower risk of developing shingles

Vaccination to prevent chickenpox (varicella) appears to have an added benefit for children—a reduced risk of shingles (herpes zoster). That's the finding of a study in the November issue of The Pediatric Infectious Disease Journal, published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

3 Dec 2009

Sepracor to present clinical study data of STEDESA at the 2009 AES meeting

Sepracor Inc. today announced that clinical study data for STEDESA™ (eslicarbazepine acetate) will be presented at the 2009 annual meeting of the American Epilepsy Society (AES) in Boston. Seven posters describing new safety analyses will be presented at the Hynes Convention Center during the formal poster session on Saturday, December 5, 2009 between 1:00 pm and 8:00 pm EST.

2 Dec 2009

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.

19 Nov 2009

Epiphany Biosciences announces results from its valomaciclovir Phase 2b trial for shingles

Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority of once-daily valomaciclovir compared to thrice-daily valacyclovir in terms of time to complete crusting of the shingles rash.

18 Nov 2009

NeoPharm presents LE-DT Phase I data at the AACR conference

NeoPharm, Inc. today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA.

18 Nov 2009